A detailed history of Ubs Asset Management Americas Inc transactions in Adaptive Biotechnologies Corp stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 118,593 shares of ADPT stock, worth $791,015. This represents 0.0% of its overall portfolio holdings.

Number of Shares
118,593
Holding current value
$791,015
% of portfolio
0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

BUY
$4.37 - $6.78 $518,251 - $804,060
118,593 New
118,593 $711,000
Q1 2024

May 15, 2024

BUY
$2.88 - $4.8 $94,029 - $156,715
32,649 Added 19.06%
203,941 $654,000
Q3 2023

Nov 13, 2023

BUY
$5.07 - $8.44 $245,261 - $408,285
48,375 Added 39.36%
171,292 $933,000
Q1 2023

May 15, 2023

BUY
$7.8 - $10.11 $83,701 - $108,490
10,731 Added 9.57%
122,917 $1.09 Million
Q4 2022

Feb 14, 2023

BUY
$6.26 - $9.34 $15,380 - $22,948
2,457 Added 2.24%
112,186 $857,000
Q3 2022

Nov 14, 2022

BUY
$6.5 - $12.67 $21,638 - $42,178
3,329 Added 3.13%
109,729 $781,000
Q2 2022

Aug 12, 2022

SELL
$6.4 - $14.73 $417,555 - $961,029
-65,243 Reduced 38.01%
106,400 $860,000
Q1 2022

May 16, 2022

BUY
$10.12 - $28.9 $164,804 - $470,636
16,285 Added 10.48%
171,643 $2.38 Million
Q4 2021

Feb 14, 2022

BUY
$25.17 - $36.85 $114,724 - $167,962
4,558 Added 3.02%
155,358 $4.36 Million
Q3 2021

Nov 15, 2021

BUY
$30.02 - $39.87 $71,867 - $95,448
2,394 Added 1.61%
150,800 $5.13 Million
Q2 2021

Aug 16, 2021

SELL
$32.22 - $44.59 $4.21 Million - $5.83 Million
-130,715 Reduced 46.83%
148,406 $6.06 Million
Q1 2021

May 14, 2021

BUY
$37.26 - $67.74 $50,822 - $92,397
1,364 Added 0.49%
279,121 $11.2 Million
Q4 2020

Mar 01, 2021

BUY
$45.01 - $65.47 $1.45 Million - $2.11 Million
32,266 Added 13.14%
277,757 $16.4 Million
Q3 2020

Nov 13, 2020

BUY
$35.79 - $48.81 $385,780 - $526,122
10,779 Added 4.59%
245,491 $11.9 Million
Q2 2020

Aug 14, 2020

BUY
$24.95 - $48.38 $4.26 Million - $8.26 Million
170,766 Added 267.05%
234,712 $11.4 Million
Q1 2020

May 15, 2020

BUY
$16.96 - $34.16 $219,174 - $441,449
12,923 Added 25.33%
63,946 $1.78 Million
Q4 2019

Feb 14, 2020

SELL
$24.56 - $32.8 $6,876 - $9,184
-280 Reduced 0.55%
51,023 $1.53 Million
Q3 2019

Nov 14, 2019

BUY
$30.31 - $53.51 $39,493 - $69,723
1,303 Added 2.61%
51,303 $1.59 Million
Q2 2019

Aug 15, 2019

BUY
$40.3 - $48.3 $2.01 Million - $2.42 Million
50,000 New
50,000 $0

Others Institutions Holding ADPT

About Adaptive Biotechnologies Corp


  • Ticker ADPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 142,872,992
  • Market Cap $953M
  • Description
  • Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signal...
More about ADPT
Track This Portfolio

Track Ubs Asset Management Americas Inc Portfolio

Follow Ubs Asset Management Americas Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.